bioAffinity Technologies Appoints New Science Team

PUBLISHED ON April 4, 2016

SAN ANTONIO, TX (April 4, 2016) bioAffinity Technologies, a privately held cancer diagnostics company, today announced that Vivienne Rebel, M.D., Ph.D., has joined the Company as Executive Vice President of Research and Development (R&D) and Chief Medical and Science Officer.

read more

bioAffinity Technologies Announces Patent Award in China

PUBLISHED ON December 14, 2015

SAN ANTONIO, TX (December 14, 2015) bioAffinity Technologies announced the People’s Republic of China awarded a Certificate of Invention Patent for the Company’s proprietary CyPath® assay, a bio-label that preferentially binds to cancer cells and labels them a brilliant crimson red that can be detected and measured by fluorescent imaging.

read more

bioAffinity Technologies is proud to play a part in the University of Texas Health video highlighting our impressive research collaboration to uncover the mechanisms of cancer. The collaboration with the University of Texas, a leader in innovation, has led to exciting advancements that further the development and commercialization of our life-saving tests and treatments for cancer. In this video, you’ll see physicians, scientists, and bioAffinity Technologies CEO Maria Zannes discuss how medical breakthroughs are being commercialized and made available to those who need them, including more about how we’re moving forward with our CyPath® diagnostic tests and OncoSelect® therapeutics.